



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 203231/S-010

SUPPLEMENT APPROVAL

ACS Dobfar Info S.A.
c/o Sagent Pharmaceuticals, Inc.
Attention: Thomas J. Moutvic
Vice President, Regulatory Affairs of Sagent Pharmaceuticals, Inc.
1901 N. Roselle Rd.
Suite 700
Schaumburg, IL 60195

Dear Mr. Moutvic:

Please refer to your Supplemental New Drug Application (sNDA) dated April 24, 2015, received April 24, 2015, pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Zoledronic Acid Injection, 4 mg/100 mL.

We also refer to our approval letter dated October 8, 2015 which contained the following error:

The drug name: Zoledronic Acid Injection (eribulin mesylate) (E7389), 4 mg/100 mL.

This replacement approval letter incorporates the correction of the error. The effective approval date will remain October 8, 2015, the date of the original approval letter.

We acknowledge receipt of your amendment dated April 28, 2015.

This "Changes Being Effected" supplemental new drug application proposes to update labeling to comply with the updated Reference Listed Drug product labeling.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content

of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert, Medication Guide), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kim J. Robertson, Regulatory Health Project Manager, at (301) 796-1441.

Sincerely,

{See appended electronic signature page}

Geoffrey S. Kim, MD
Director
Division of Oncology Products 1
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

GEOFFREY S KIM
10/08/2015